Linaclotide vs Larazotide
Head-to-head comparison of Linaclotide (Linaclotide) and Larazotide (Larazotide acetate (AT-1001)) — benefits, dosing, side effects, research data, and where to buy.
Research Score
| Property | Linaclotide | Larazotide |
|---|---|---|
| Category | Gastrointestinal | Gastrointestinal |
| Full Name | Linaclotide | Larazotide acetate (AT-1001) |
| Molecular Weight | 1526.8 Da | N/A |
| Half-Life | Active locally; negligible systemic half-life | short; designed for local gut action |
| Amino Acids | 14 | 8 |
| Typical Dose | 72-290 mcg once daily | 0.5-4 mg TID (clinical studies) |
| Route | Oral | Oral |
| Purity | ≥98% | ≥98% |
| Studies Count | 1200 | 40 |
| Research Status | Clinical | Clinical |
Linaclotide Benefits
- ✓improves-bowel-movements
- ✓reduces-abdominal-pain
- ✓increases-intestinal-secretion
- ✓supports-transit
Larazotide Benefits
- ✓tight-junction-support
- ✓reduced-permeability
- ✓symptom-reduction
- ✓barrier-protection
Linaclotide Dosing
72 mcg PO daily|145 mcg PO daily|290 mcg PO daily
Larazotide Dosing
0.5-4 mg orally before meals in clinical trials|typically three times daily|short-course or chronic study protocols
Linaclotide Side Effects
- ⚠diarrhea
- ⚠abdominal-pain
- ⚠bloating
Larazotide Side Effects
- ⚠headache
- ⚠nausea
- ⚠abdominal discomfort
Research Overview
Linaclotide
Linaclotide has extensive clinical evidence for chronic idiopathic constipation and IBS-C, with consistent effects on stool frequency and abdominal symptom relief. Its mechanism is local GC-C activation in the gut with minimal systemic exposure.
Larazotide
Clinical and translational studies suggest larazotide can reduce antigen passage across the epithelium and improve gut barrier function. It is one of the better-known peptides for intestinal permeability and barrier-focused gastrointestinal therapy.
Ready to buy?
Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.